Literature DB >> 1668105

Tumor necrosis factor release by human monocytes stimulated with platelet-activating factor.

N M Ruis1, J K Rose, F H Valone.   

Abstract

Platelet-activating factor (PAF) is a low molecular weight phospholipid which enhances human monocyte cytotoxicity for tumor cells. In the current studies, the capacity of PAF to stimulate release of tumor necrosis factor alpha (TNF alpha) by human monocytes was assessed. PAF induced maximal TNF alpha synthesis 2-3 hr after monocyte stimulation as assessed by dot blotting of cell-associated TNF alpha using polyclonal anti-TNF antibody. Maximal net release of TNF alpha occurred 5-16 hr after monocyte stimulation, as assessed by a specific ELISA. Dose-response studies revealed that a maximal two- to three-fold increase in release of TNF alpha occurs at 10-100 pM PAF. LysoPAF and the optical isomer of PAF did not stimulate release of TNF alpha, suggesting that stimulation is mediated by specific PAF receptors. Scatchard analysis of [3H]PAF binding to monocyte membranes revealed 651 +/- 495 binding sites/monocyte with a Kd of 4.7 +/- 4.2 x 10(-10) M. PAF is a structurally unique activator of monocytes whose interactions with TNF alpha and other cytokines may be critical to host defense against tumors.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1668105     DOI: 10.1007/bf02536502

Source DB:  PubMed          Journal:  Lipids        ISSN: 0024-4201            Impact factor:   1.880


  25 in total

1.  Bowel necrosis induced by tumor necrosis factor in rats is mediated by platelet-activating factor.

Authors:  X M Sun; W Hsueh
Journal:  J Clin Invest       Date:  1988-05       Impact factor: 14.808

2.  Association of platelet-activating factor with primary acquired cold urticaria.

Authors:  K E Grandel; R S Farr; A A Wanderer; T C Eisenstadt; S I Wasserman
Journal:  N Engl J Med       Date:  1985-08-15       Impact factor: 91.245

3.  Platelet-activating factor (PAF) enhances tumor necrosis factor production by alveolar macrophages. Prevention by PAF receptor antagonists and lipoxygenase inhibitors.

Authors:  C Dubois; E Bissonnette; M Rola-Pleszczynski
Journal:  J Immunol       Date:  1989-08-01       Impact factor: 5.422

4.  Effect of platelet-activating factor (PAF-acether) and its specific receptor antagonist, BN 52021, on interleukin 1 (IL1) release and synthesis by rat spleen adherent monocytes.

Authors:  B Pignol; S Hénane; J M Mencia-Huerta; M Rola-Pleszczynski; P Braquet
Journal:  Prostaglandins       Date:  1987-06

5.  Modulation of in vitro immune reactions by platelet activating factor and a platelet activating factor antagonist.

Authors:  B M Gebhardt; P Braquet; H Bazan; N Bazan
Journal:  Immunopharmacology       Date:  1988 Jan-Feb

6.  Tumor necrosis factor production by human monocytes is a regulated event: induction of TNF-alpha-mediated cellular cytotoxicity by endotoxin.

Authors:  R S Kornbluth; T S Edgington
Journal:  J Immunol       Date:  1986-10-15       Impact factor: 5.422

7.  Enhanced human monocyte cytotoxicity by platelet-activating factor.

Authors:  F H Valone; R Philip; R J Debs
Journal:  Immunology       Date:  1988-08       Impact factor: 7.397

8.  Specific binding by human polymorphonuclear leucocytes of the immunological mediator 1-O-hexadecyl/octadecyl-2-acetyl-sn-glycero-3-phosphorylcholine.

Authors:  F H Valone; E J Goetzl
Journal:  Immunology       Date:  1983-01       Impact factor: 7.397

9.  Biphasic platelet-activating factor synthesis by human monocytes stimulated with IL-1-beta, tumor necrosis factor, or IFN-gamma.

Authors:  F H Valone; L B Epstein
Journal:  J Immunol       Date:  1988-12-01       Impact factor: 5.422

10.  Immune regulation by platelet-activating factor. I. Induction of suppressor cell activity in human monocytes and CD8+ T cells and of helper cell activity in CD4+ T cells.

Authors:  M Rola-Pleszczynski; C Pouliot; S Turcotte; B Pignol; P Braquet; L Bouvrette
Journal:  J Immunol       Date:  1988-05-15       Impact factor: 5.422

View more
  4 in total

1.  Platelet-activating factor augments meningeal inflammation elicited by Haemophilus influenzae lipooligosaccharide in an animal model of meningitis.

Authors:  G C Townsend; W M Scheld
Journal:  Infect Immun       Date:  1994-09       Impact factor: 3.441

2.  Stimulation of tumour necrosis factor release by cytotoxic analogues of platelet-activating factor.

Authors:  F H Valone; N M Ruis
Journal:  Immunology       Date:  1992-05       Impact factor: 7.397

3.  Involvement of platelet-activating factor in ultraviolet B-induced hyperalgesia.

Authors:  Qiwei Zhang; Leslie A Sitzman; Mohammad Al-Hassani; Shanbao Cai; Karen E Pollok; Jeffrey B Travers; Cynthia M Hingtgen
Journal:  J Invest Dermatol       Date:  2008-06-26       Impact factor: 8.551

4.  In vivo effect of two first-line ART regimens on inflammatory mediators in male HIV patients.

Authors:  Vasiliki D Papakonstantinou; Maria Chini; Nikos Mangafas; George M Stamatakis; Nickolaos Tsogas; Alexandros B Tsoupras; Katherina Psarra; Elizabeth Fragopoulou; Smaragdi Antonopoulou; Panagiotis Gargalianos; Constantinos A Demopoulos; Marios-C Lazanas
Journal:  Lipids Health Dis       Date:  2014-05-29       Impact factor: 3.876

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.